Glenmark will be able to distribute generic version of anti-depression drug Savella in the US market following a settlement in a patent litigation with Forest Laboratories. The drug maker announced today that it has settled the dispute related to its application to distribute generic version of tablets of various strength. According to IMS Health sales data for the 12-month period ending October 2015, Savella achieved annual sales of approximately $134.7 million.
Glenmark's current portfolio consists of 103 products authorised for distribution in the U.S. market and 63 abbreviated new drug applications are pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, the company said in a statement.